CVE:KNE Kane Biotech (KNE) Stock Price, News & Analysis → Claim Your FREE 'AI Income Playbook' Now! (From The Oxford Club) (Ad) Free KNE Stock Alerts C$0.14 +0.01 (+7.69%) (As of 06/14/2024 05:23 PM ET) Add Compare Share Share Today's RangeC$0.14▼C$0.1450-Day RangeC$0.12▼C$0.1652-Week RangeC$0.05▼C$0.17Volume1,000 shsAverage Volume124,310 shsMarket CapitalizationC$18.55 millionP/E RatioN/ADividend Yield3.08%Price TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesStock AnalysisChartEarningsHeadlines Get Kane Biotech alerts: Email Address Ad The Oxford ClubClaim Your FREE "AI Income Playbook" Now!Income expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Playbook" - and it's yours FREE!Click here now to claim your FREE copy of Marc's AI playbook. About Kane Biotech Stock (CVE:KNE)Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.Read More KNE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KNE Stock News HeadlinesMay 28, 2024 | yahoo.comPatrick Kane is King William High's new athletics directorMay 24, 2024 | finanznachrichten.deKane Biotech Inc.: Kane Biotech Announces First Quarter 2024 Financial ResultsMay 23, 2024 | finance.yahoo.comKane Biotech Announces First Quarter 2024 Financial ResultsMay 15, 2024 | finance.yahoo.comKane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound MapApril 30, 2024 | msn.comHarry Kane on target but Vinicius Jr brace earns Real Madrid first-leg drawApril 28, 2024 | reuters.comKane double steers Bayern 2-1 past Frankfurt ahead of Real clashApril 27, 2024 | msn.comKane sets personal record with double in Bayern winApril 16, 2024 | finanznachrichten.deKane Biotech Inc.: Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary ProductsApril 16, 2024 | tmcnet.comKane Biotech to Host Investor WebinarApril 15, 2024 | msn.comDual Listed Biotech Firm Achieves Sale of Animal Health Interest, Sending Shares HigherApril 15, 2024 | stockhouse.comKane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary ProductsApril 12, 2024 | barrons.com'Light Injuries': Harry Kane's Children In Munich Car AccidentApril 11, 2024 | finanznachrichten.deKane Biotech Inc.: Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal HealthApril 11, 2024 | ca.finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - KNEApril 11, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - KNEMarch 29, 2024 | finanznachrichten.deKane Biotech Inc.: Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 27, 2024 | finance.yahoo.comKane Biotech Announces Fourth Quarter and Full Year 2023 Financial ResultsMarch 20, 2024 | finance.yahoo.comKane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal HealthMarch 8, 2024 | tmcnet.comKane Biotech Receives Bioscience Association Manitoba Company of the Year AwardFebruary 24, 2024 | msn.comChicago Blackhawks brace for Patrick Kane’s return — as a Detroit Red Wing: ‘It’s definitely weird’January 31, 2024 | finanznachrichten.deKane Biotech Inc.: Kane Biotech Files New Patent on revyve Antimicrobial Wound Gel SprayJanuary 31, 2024 | financialpost.comKane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel SprayJanuary 31, 2024 | stockhouse.comKane Biotech Files New Patent on revyve(TM) Antimicrobial Wound Gel SprayJanuary 25, 2024 | markets.businessinsider.comKane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care SymposiumJanuary 18, 2024 | finance.yahoo.comKane Biotech Announces Special Meeting of ShareholdersSee More Headlines Receive KNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kane Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/23/2024Today6/15/2024Next Earnings (Estimated)9/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:KNE CUSIPN/A CIKN/A Webwww.kanebiotech.com Phone+1-204-4531301FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-4,940,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-40.64% Debt Debt-to-Equity Ratio1,164.24 Current Ratio0.31 Quick Ratio0.39 Sales & Book Value Annual SalesC$2.74 million Price / Sales6.77 Cash FlowC$0.02 per share Price / Cash Flow8.50 Book ValueC($0.08) per share Price / Book-1.75Miscellaneous Outstanding Shares132,510,000Free FloatN/AMarket CapC$18.55 million OptionableNot Optionable Beta0.55 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Marc EdwardsPresident, CEO & DirectorMr. Ray DupuisChief Financial OfficerMr. Kevin ColePresident & CEO of STEM Animal Health IncMr. Dena MehrabanGeneral Manager of STEM Animal Health IncDr. Robert B. Huizinga CNeph(C) (Age 58)M.Sc., MSc(Epi), Ph.D., R.N., RN NNC, Executive Chairman & Member of Scientific Advisory Board Dr. Gregory S. Schultz Ph.D. (Age 74)Chief Scientific Officer & Member of Scientific Advisory Board Lorne GorberInvestor RelationsMs. Lori ChristofalosVice President of Quality & ComplianceMs. Wendy NachtigallDirector of MarketingNicole SendeyInvestor Relations AdviserMore ExecutivesKey CompetitorsPediapharmCVE:PDPHelix BioPharmaTSE:HBPEmerald Health TherapeuticsCVE:EMHProMIS NeurosciencesTSE:PMNSmall PharmaCVE:DMTView All CompetitorsInsidersPhilip RenaudSold 2,000,000 sharesTotal: C$260,000.00 ($0.13/share)Richard J. RenaudBought 3,125,000 shares on 9/11/2023Total: C$250,000.00 ($0.08/share) KNE Stock Analysis - Frequently Asked Questions How have KNE shares performed in 2024? Kane Biotech's stock was trading at C$0.08 at the beginning of the year. Since then, KNE shares have increased by 75.0% and is now trading at C$0.14. View the best growth stocks for 2024 here. When is Kane Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 3rd 2024. View our KNE earnings forecast. How were Kane Biotech's earnings last quarter? Kane Biotech Inc. (CVE:KNE) posted its earnings results on Thursday, May, 23rd. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm had revenue of $0.05 million for the quarter. How do I buy shares of Kane Biotech? Shares of KNE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:KNE) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kane Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kane Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.